# What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

- Source: PR Newswire
- Published: 2026-10-23T18:10:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/whats-next-for-unicycive-therapeutics-inc-shareholders-after-39-1-stock-drop-glancy-prongay-wolke--rotter-llp-explains-securities-fraud-class-action-lead-plaintiff-deadline-302917636.html
- Canonical: https://groundlevelnews.com/story/what-s-next-for-unicycive-therapeutics-inc-shareholders-after-39-1-sto-0c1871/

Complaint alleges Unicycive Therapeutics, Inc. misled investors between December 29, 2025 and June 29, 2026; investors may seek lead plaintiff role by November 2, 2026 LOS ANGELES, Oct. 23, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._